Skip to content

TALENT-Study Stress - A randomized controlled trial to investigate the effectiveness of a lifestyle program (IHM-SEPP) on stress symptoms

TALENT-Study Stress - A randomized controlled trial to investigate the effectiveness of a lifestyle program (IHM-SEPP) on stress symptoms - TALENT-Study II Stress

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00013040
Enrollment
136
Registered
2017-10-11
Start date
2017-10-14
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Z72 Z73

Interventions

Group 1: Lifestyle program IHM-SEPP (Individual Health Management - Sino-European Prevention Programm): access to a web-based health portal (www.viterio.de) and join of 3 full-day and 10 2-hour traini

Sponsors

Technische Hochschule Deggendorf - Fakultät Angewandte Gesundheitswissenschaften
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: - Tedium-Measure = 3,20 (= moderate stress/pre-burnout) - PSQ total score (Perceived Stress Questionnaire) > 41 - Subjective feeling of stress exposure for more than 3 months - informed consent

Exclusion criteria

Exclusion criteria: - being unable to consent for themself - insufficient skills in German language - no private access to internet - known hypertension (systolic blood pressure = 160 mmHg or diastolic blood pressure = 100 mmHg) with or without medication - known hypotension (systolic blood pressure = 70 mmHg or diastolic blood pressure = 50 mmHg) - body mass index (BMI) < 17,5 - psychiatric/psychotherapeutic treatment requirements defined as "severe signs and symptoms" according to the ISR (ICD-10-Symptom Rating) questionnaire in at least one of the subcales depressive syndrome, anxiety syndrome, obsessive-compulsive syndrome, somatoform syndrome, eating disorder syndrome or in the ISR total score - known psychiatric treatment (with or without medication) - known diabetes mellitus (type 1 or 2) - known heart disease (like CHD, arrhythmia, valvular heart defect, cardiac insufficiency) - known gastric or duodenal ulcers - known diseases of the liver or kidneys - known diseases of the eyes (e.g. retinal detachment) - known disease of the thyroid gland or taking of thyroid hormones - known disease-related impairments preventing a participation in the lifestyle program (e.g. arthrosis) - known therapeutic conditions that are due to known risiks/side effects not compatible with participation in the lifestyle program - known pregnancy (or lactation) or planned in the next year - participation in another currently cinical trial or during the last 6 months

Design outcomes

Primary

MeasureTime frame
Change in perceived stress (PSQ total score; Perceived Stress Questionnaire) after 6 months

Secondary

MeasureTime frame
Tedium-Measure, ICD-10-Symptom-Rating (ISR), tcm diagnosis, tcm constitution, heart rate variability (HRV), heart rate, laboratory findings, waist circumference, blood pressure, stresses and strains, 3-level-stresstest, severity of mood state in general (VAS), life satisfaction (FLZ), WHO-5-well-being, self-efficacy, optimism and pessimism (SWOP), motivation and willingness to change, sense of coherence (SOC-13), social support (SSS), psycho-vegetative test, comprehensive medical history, cardiovascular and metabolic risk factors, hypertension risk, diabetes risk (findrisk), nutrition index, moving index, physical power and the body’s defenses. Examinations are conducted at months 0, 3 and 6. In the intervention group additional examinations are carried out in the course of a longitudinal analysis in months 9 and 12.

Countries

Germany

Contacts

Public ContactLisa Dersch

Kompetenzzentrum für Komplementärmedizin und Naturheilkunde (KoKoNat), Fakultät Angewandte Gesundheitswissenschaften der Technischen Hochschule Deggendorf

kokonat@th-deg.de0991 36158551

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 6, 2026